CDC study: Number of TFAs in blood levels on decline
ATLANTA — The amount of trans fats found in blood levels of U.S. white adults has significantly dropped over a nine-year period, according to a study conducted by the Centers for Disease Control and Prevention.
The study, published in the Feb. 8 edition of the Journal of the American Medical Association pooled participants from the CDC’s National Health and Nutrition Examination Survey in 2000 and 2009. The goal was to examine trans-fatty acid blood levels among this demographic before and after the Food and Drug Administration’s 2003 regulation — which took effect in 2006 — that required manufacturers to list the amount of TFAs on the Nutrition Facts panel of a food or dietary supplement product label. The researchers found that TFAs found in blood levels decreased by 58%. The consumption of trans fats increases the risk of coronary heart disease, the CDC noted.
Full details of the study can be viewed here.
"The 58% decline shows substantial progress that should help lower the risk of cardiovascular disease in adults," said Christopher Portier, director of CDC’s National Center for Environmental Health. "Findings from the CDC study demonstrate the effectiveness of these efforts in reducing blood TFAs and highlight that further reductions in the levels of trans fats must remain an important public health goal."
Portier added that while the study only provides information regarding TFAs among white adults, additional CDC studies are under way to examine blood TFAs in other adult race/ethnic groups, children and adolescents.
Great to see we're eating less, but looks like the only safe intake is zero: nutritionfacts.org/videos/trans-fat-saturated-fat-and-cholesterol-tolerable-upper-intake-of-zero/
The Apothecary Shops to distribute new Pfizer cancer drug
PHOENIX — Specialty pharmacy provider The Apothecary Shops has inked a deal with Pfizer to distribute a new drug for treating kidney cancer.
The specialty provider announced Wednesday that Pfizer had granted it distribution rights for Inlyta (axitinib), which the Food and Drug Administration approved on Jan. 27 for advanced renal cell carcinoma in patients who have failed one systemic therapy.
"The Apothecary Shops is excited to be included in the limited network of pharmacies managing Inlyta," The Apothecary Shops president Keith Cook said. "We have a first-class oncology team, and this announcement certainly reinforces our strong position in the oncology market."
No comments found
Watson, J&J settle lawsuit over generic contraceptive
PARSIPPANY, N.J. — Subsidiaries of Watson Pharmaceuticals and Johnson & Johnson have settled a lawsuit filed by the latter when Watson attempted to market a generic version of one of its contraceptive drugs.
Watson said Wednesday that Watson Labs and Janssen Pharmaceuticals had settled a patent litigation suit filed in October 2008 over the drug Ortho Tri-Cyclen Lo (norgestimate and ethinyl estradiol). Janssen filed the suit after Watson sought Food and Drug Administration approval for the drug prior to the expiration of a patent covering it; the patent covering the drug’s use in adults is scheduled to expire in June 2019, according to FDA records.
Under the settlement, Janssen will manufacture and supply Watson with an authorized generic version of the drug, while Watson will have the right to market and distribute it and the end of 2015. Other terms of the deal were not disclosed.
No comments found